Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cend Therapeutics
New regulatory measures shorten clinical trial approval times and usher in busy deal-making between large makers and smaller biotechs outside China.
Plus deals involving Scynexis/Hansoh, Cend/Qilu, Apollomics/Edison, Apollomics/Iterion, Apollomics/Nuance, Aerami/Chance, Antibe/Nuance, Ildong/Arbormed
Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.
- Drug Delivery
- Other Names / Subsidiaries
- DrugCendR Inc
- Impilo Therapeutics, Inc.